Tomasz Jankowski, Mariola Kowal-Rosinska, Veronika Müller, Ahmet Sezer, Tibor Csoszi, Tünde Nagy, Rodryg Ramlau, Szabolcs Soter, Razvan Bobora, Florin Amurariti, Constantin D. Volovat, Daniela E. Sirbu, Ilgen Mender, Romina Girotti, Marcel Mitsunaga, Oleg Tudos, Matthew Failor, Vlad Vitoc, Sergei Gryaznov, Victor Zaporojan. "Phase 2 study of PFS in third-line immune checkpoint inhibitor–resistant advanced NSCLC treated with the telomere-targeting agent ateganosine (THIO; 6-thio-2'-deoxyguanosine) sequenced with ICI.." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.16_suppl.e20610